Test Price
2,800 AEDโ Home Collection Available
EGFR Gene Exons 18-21 Selective Sequencing (NGS) Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
Executive Summary
This next-generation sequencing assay provides precise detection of actionable EGFR exon 18-21 mutations, directly informing tyrosine kinase inhibitor therapy decisions in advanced non-small cell lung cancer. The test is performed at a DHA-licensed facility with ISO 9001:2015 accreditation and full compliance with UAE federal data protection frameworks. Patients receive VIP mobile phlebotomy, temperature-controlled cold-chain logistics, and post-test clinical guidance from our genetics team.
ISO 9001:2015 accredited NGS analysis (Cert: INT/EGQ/2509DA/3139)
VIP mobile phlebotomy with ISO-certified cold-chain, 8 AM โ 11 PM
Telephonic interpretation support by our genetics and oncology team
Quick verification via WhatsApp +971 54 548 8731
Test Overview & Methodology
This selective sequencing assay uses next-generation technology to analyze exons 18 through 21 of the EGFR gene, identifying single-nucleotide variants, insertions, and deletions that drive oncogenic signaling in non-small cell lung cancer. Detection of these mutations enables oncologists to select the most appropriate tyrosine kinase inhibitor, improving progression-free survival and overall response rates. The assay achieves variant allele frequency detection down to 0.1% and is performed on the Illumina® platform with rigorous quality controls.
| Feature | Our Test (EGFR NGS) | Closest Alternative (PCR Single-Exon) |
|---|---|---|
| Precision | Full exon 18-21 coverage with variant allele frequency detection down to 0.1% | Limited to pre-specified hotspots; may miss rare mutations |
| Methodology | NGS (Next-Generation Sequencing) on Illumina® platform | Real-time PCR or Sanger sequencing |
| Turnaround Time | 15-20 business days (3-4 weeks) | 5-10 business days |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics, I consider EGFR exon 18-21 sequencing essential for identifying actionable driver mutations that guide tyrosine kinase inhibitor therapy in non-small cell lung cancer. A negative result does not preclude other genomic alterations, and all findings must be interpreted within the full clinical context. Treatment decisions should always be made in consultation with your oncology team.”
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
โ ๏ธ Medication Advisory
Do not discontinue or alter any prescribed medication without consulting your treating physician. Genetic test results are one component of comprehensive oncologic care and must be integrated with your full medical history and current treatment plan.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Active systemic infection or sepsis; platelet count below 20,000/ยตL; inability to provide informed consent; ongoing anticoagulant therapy that cannot be safely paused for collection.
- Emergency Red Flags โ Seek Immediate Medical Attention: Sudden severe pain at venipuncture site, active heavy bleeding, loss of consciousness, or signs of anaphylaxis such as swelling or breathing difficulty following collection.
Patient FAQ & Clinical Guidance
1. What is the EGFR gene test and why is it important for lung cancer?
The EGFR gene test identifies mutations in exons 18-21, guiding targeted therapy for lung cancer patients. This information helps oncologists select the most effective tyrosine kinase inhibitor, improving response rates and survival outcomes in advanced non-small cell lung cancer.
2. How is the sample collected and is a hospital visit required?
A blood sample is collected at your home via VIP mobile phlebotomy, with no hospital visit needed. Our certified mobile team uses a DNA FTA card or whole blood tube, maintaining cold-chain integrity from collection to laboratory processing.
3. What is the turnaround time and how will I receive results?
Results are delivered within 15-20 business days through a secure, encrypted medical report portal. You will receive an email notification when your report is ready, and a genetic counselling session can be scheduled to discuss the findings and their implications for your care.
UAE Regulatory & Data Privacy Adherence
๐ Your Data, Your Rights
DNA Labs UAE operates under DHA Facility License No. 1143 and complies fully with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, stored securely, and never shared without your explicit consent. Clinical safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | EGFR Gene Exons 18-21 Selective Sequencing (NGS) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 15-20 Business Days (3-4 Weeks) |
| Sample Type / Matrix | Peripheral Whole Blood or DNA Specimen (FTA Card / Whole Blood Tube) |
| Methodology Used | Next-Generation Sequencing (NGS) โ Illumina® Platform |
| ICD-10-CM Code | C34.9, Z85.1 |
| LOINC Code | 57186-8 |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians